Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Acute leukemias: the doubled-edged sword of genetic complexity

Tariq Mughal • 25 Feb 2019
ISAL 2019
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Acute leukemias are genetically heterogeneous, making their targeted therapy more complex. We spoke to Tariq Mughal, MD, MB, BS, MRCS, MRCP, FRCP, of Tufts University School of Medicine, Boston, MA, about our understanding of the genetic complexity of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Tariq Mughal

2:25
The importance of genetic profiling: NGS, MRD & beyond
Tariq Mughal • 25 Feb 2019
4:15
Precision medicine in hematological oncology: development to the present day
Tariq Mughal • 25 Feb 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals